New MS Diagnosis Rules Speed Up Care for First Symptoms

Credibility

Interest

Key Takeaway

The 2017 MS diagnostic rules find more people earlier after a first nervous-system attack, which can shorten how long it takes to start treatment.

What They Found

Researchers followed 201 people in Argentina after their first demyelinating event (a first attack where nerve insulation is damaged, like the plastic coating on an electric wire getting nicked). The 2017 McDonald rules were better at catching people who later developed definite MS (they were more sensitive), so more patients were identified sooner than with the older 2010 rules. Being more sensitive meant the 2017 rules also picked up more false alarms (they were less specific), so some people might be labeled likely MS when they do not go on to get definite MS. Patients who had positive oligoclonal bands in spinal fluid (these are proteins that suggest inflammation in the brain or spinal cord, similar to finding fingerprints at a scene) were especially likely to be identified by the 2017 criteria. Genetic testing in part of the group showed most patients (72%) had mainly European ancestry, while about 27% had mixed ancestry, meaning these results come from a population with varied genetic backgrounds.

Who Should Care and Why

People with MS or a first demyelinating attack should care because the 2017 rules can lead to an earlier diagnosis and therefore earlier discussion about treatment and symptom planning, similar to detecting a leak earlier so you can fix it before more damage happens. Caregivers can use earlier diagnosis to plan support, like arranging therapy, home help, or workplace changes sooner rather than later. Clinicians and MS nurses benefit because they can use the updated rules to decide when to monitor more closely or begin treatment, balancing the need to act early with confirming the diagnosis. Patients with positive spinal fluid tests (oligoclonal bands) should know these tests make the 2017 rules especially likely to point toward MS, which might speed decision-making. Because the study used people from Argentina with mostly European or mixed ancestry, the findings are most directly useful to similar populations, but the idea of earlier diagnosis may apply broadly.

Important Considerations

The study had only 201 people and fewer genetic tests (128), so results might not apply exactly the same way to all countries or ethnic groups. The 2017 rules pick up more true MS cases but also more cases that turn out not to be MS, so an earlier label can cause worry or lead to treatments that might not have been needed. This study shows what happened in Argentina; your doctor will still weigh your symptoms, tests, and risks before making a diagnosis or starting treatment.

AI-generated summary — for informational purposes only, not medical advice

Categories:

MS Diagnostics MS Genetics Early Research

Article Topics:

CISMRIMultiple sclerosis

Whether you’ve recently been diagnosed with Multiple Sclerosis (MS) or are seeking to broaden your understanding of this complex, neurodegenerative disease, navigating the latest research can feel overwhelming. Studies published in respected medical journals like Multiple sclerosis (Houndmills, Basingstoke, England) often range from early-stage, exploratory work to advanced clinical trials. These evidence-based findings help shape new disease-modifying therapies, guide symptom management techniques, and deepen our knowledge of MS progression.

However, not all research is created equal. Some clinical research studies may have smaller sample sizes, evolving methodologies, or limitations that warrant careful interpretation. For a more comprehensive, accurate understanding, we recommend reviewing the original source material—accessible via the More Details section above—and consulting with healthcare professionals who specialize in MS care.

By presenting a wide range of MS-focused studies—spanning cutting-edge treatments, emerging therapies, and established best practices—we aim to empower patients, caregivers, and clinicians to stay informed and make well-informed decisions when managing Multiple Sclerosis.

Back to News